1398TiP Be6A Lung-01, a phase III study of sigvotatug vedotin (SV), an investigational antibody-drug conjugate (ADC) versus docetaxel in patients (pts) with previously treated non-small cell lung cancer (NSCLC)
2024 · Annals of Oncology · 2 citations
https://doi.org/10.1016/j.annonc.2024.08.1453